#### **ADVISORY COMMITTEE ON ANIMAL FEEDINGSTUFFS**

64th Meeting of ACAF on 9 May 2014

Presentation Paper Phil Sketchley – Chief Executive NOAH

#### EUROPEAN INITIATIVES TO MONITOR ANTIBIOTIC RESISTANCE AND USAGE AND INDUSTRY PERSPECTIVES FOR THE FUTURE

Secretariat April 2014



European initiatives to monitor antibiotic resistance and usage and industry perspectives for the future

## Phil Sketchley Chief executive, NOAH





#### NOAH

- The National Office of Animal Health (NOAH) represents
   the UK animal medicines industry
- Represents UK industry with the regulatory agencies and at IFAH Europe
- Aim is to promote the benefits of safe, effective, quality medicines for the treatment and welfare of all animals.
- 23 Corporate Members, approximately 90% of UK vet medicines industry
- Member of RUMA (Responsible Use of Medicines in Agriculture Allaince)





# Industry Perspective on Antimicrobial Resistance

- General points on Antimicrobial Resistance and the UK perspective
- European perspective-actions taken to date in different Member States
- European Legislative review
- Industry perspective on antimicrobial resistance and the future legislation changes





#### **General Points on Antimicrobial resistance**

- Industry wants for its products to remain effective for as long as possible- best achieved by the promotion of and adherence to responsible use by vets and farmers
- Appropriate regulatory climate is needed to encourage industry to continue to invest in R and D in animal health
- High costs to market- c. 150 million euros to develop a livestock medicine- need confidence that ROI achievable





#### **General Points on Antimicrobial resistance**

- Measurement of resistance across EU Member States and in different reports - little consensus - different countries/institutions gather data and measure resistance in different ways
- Makes comparisons between reports and between Member States' data difficult - Clinical Resistance vs Epidemiological Cut-off Values
- ECV- reduced susceptibility, true clinical resistance is the clinical break points
- Lab detected 'reduced susceptibility '- often referred to as 'resistance' in some reports





#### **Clinical breakpoints vs epidemiological cut-off values**

• "Epidemiological resistance" not necessarily clinically relevant!



WT = Wild type organisms, i.e micro-organisms without phenotypically detectable antimicrobial resistance to the drug in question

S = Susceptible; I = Intermediate; R = Resistant

Selected References: EU Community Reference Laboratory - Antimicrobial Resistance newsletter No 2 2007

National Office of Animal Health

## **Antibiotic resistance - UK**

- UK Department of Health 5 year strategy on AMR published Sept 2013
- UK Parliament Science and Technology Committee inquiry into AMR - awaiting report
- International dimension of resistance acknowledged people and foodstuffs moving all over world - little control in developing world
- Strategy acknowledges human use the main driver of human resistance problems;
- 'Increasing scientific evidence suggests that the clinical issues with antimicrobial resistance that we face in human medicine are primarily the result of antibiotic use in people, rather than antibiotics in animals'.

Point 2.1, page 8 Department of Health UK 5 Year Antimicrobial Resistance Strategy 2013 to 2018. <u>https://www.gov.uk/government/publications/uk-5-year-antimicrobial resistance-strategy-2013-to-2018</u>

#### **Antibiotic resistance - UK**

- Recent scientific papers from Mather et al (2013) on Salmonella, Wu et al (2013) on ESBLs in poultry support the D o H view
- Resistance in vet pathogens rare unusual for a sick animal with bacterial infection to fail to respond to treatment where the appropriate antibiotic is used
- More research is needed on resistance surveillance and transmission pathways (likely to be included in new EU Vet med legislation)

#### References;

Wu G, Day MJ, Mafura MT, Nunez-Garcia J, Fenner JJ, et al. (2013) Comparative Analysis of ESBL-Positive Escherichia coli Isolates from Animals and Humans from the UK, The Netherlands and Germany. PLoS ONE 8(9): e75392. doi:10.1371/journal.pone.0075392

Mather AE, Reid SWJ et al, (2013)Distinguishable epidemics of multidrug-resistant Salmonella Typhimurium DT104 in different hosts. Science 341, 1514-1517.

#### **Implementation of the UK 5 year strategy**

 RUMA action plan to implement launched and published – will be reviewed quarterly

#### **UK 5 YEAR ANTIMICROBIAL RESISTANCE (AMR) STRATEGY**

#### ACTION PLAN FOR THE RESPONSIBLE USE OF MEDICINES IN AGRICULTURE ALLIANCE (RUMA) AND ITS INDIVIDUAL MEMBERS

1. The UK 5 year AMR Strategy was launched on 10 September 2013. RUMA, a unique alliance of 23 organisations across the whole UK livestock sector, was among the groups that welcomed and supported the strategy.

2. The Alliance has discussed the actions that will be required to implement the strategy and has developed this action plan, based on the detailed actions in Annex B of the Strategy, to set out the actions that RUMA and/or its members will take. Inevitably, the plan is still at an early stage. RUMA members have agreed to review and record progress against the plan at RUMA's quarterly meetings and to publish the plan and its subsequent revisions to provide an open report on how this work is developing. During these reviews new actions will be added to the plan including any identified by the high level steering group made up of DARC, ARHAI and ACSMF members who the strategy says will agree an action plan to implement the strategy.

3. A list of RUMA members and the acronyms used in this plan are at Annex A.

4. If you have any comments on the plan please send them to RUMA's Secretary General, John FitzGerald, at <a href="mailto:rumasec@btinternet.com">rumasec@btinternet.com</a>.

RUMA April 2014

Strategy actions – Annex B	Section 5.6 Actions for Animal Health (Bold added by RUMA)	RUMA/members' action	Progress
Actions needed to further improve infection prevention and control in human and animal systems are:	<ul> <li>considering the use of farm assurance schemes as a mechanism to increase adherence to best husbandry including isolation of sick animals, testing of new stock and responsible use of antibiotic principles, while ensuring animal health and welfare.</li> </ul>	RUMA will need to help develop improved infection prevention and control practices and to disseminate advice on them through RUMA Guidelines or advice notes.	
	NFU, Species Groups, Red Tractor - encouraging retailers to review their standards for meat and animal products and to set clear specifications, concerning bio- security, antimicrobial stewardship and good	RUMA to develop protocols for members' advisory staff to ensure they are able to provide up to date advice on antibiotic resistance and responsible use when they interact with farmers.	

..... Office of Animal Health

#### **Antibiotic resistance- restriction of classes**

- Class related restrictions- comments from human sector, submission from Public Health England to UK Parliament Science and Technology Committee inquiry;
- One major uncertainty, despite the agreed need for antimicrobial stewardship to prevent and slow resistance, is exactly what good stewardship looks like. <u>There is a tendency in the UK to equate stewardship with simply minimising use of antibiotics such as cephalosporins and fluoroquinolones.</u> Consequently, there have been major increases in the use of a very narrow range of alternative antibiotics, especially an antibiotic called piperacillin-tazobactam. <u>This can be equated to 'squeezing the balloon' by potentially creating a resistance problem elsewhere.</u> Rather than 'swinging the pendulum' away from use of what might be the most effective antibiotic for the patient (e.g. use of cephalosporins), <u>improving knowledge about appropriate prescribing is required.</u>

Source-

http://data.parliament.uk/writtenevidence/WrittenEvidence.svc/EvidenceHtml/3415





#### Antibiotic resistance- regulatory climate

- Antibiotic resistance one of the issues under consideration as part of EU revision of the Veterinary Medicines legislation
- Animal health industry- great concern that a new veterinary antibiotic would be unlikely to be licensed by regulators or would have requirements in authorisation that would severely limit the use
- Regulatory uncertainty around antibiotic resistance acts as major disincentive for companies considering research pipeline
- Precautionary approach rather than evidence based





#### **Antibiotic resistance- regulatory climate**

- Veterinary bodies and industry- all wish to retain use of Critically Important Antibiotics (CIA) for veterinary use
- What is classed as CIA varies depending on what body you consult with and also changes over time - ban on CIAs could really limit future vet antibiotics
- Ban on CIAs can lead to overuse of remaining classes lead to resistance to remaining products
- Necessary to retain all classes for animal health and welfare reasons





#### **European Legislative Review**

- Review of the EU regulatory framework for veterinary medicines underway
- Antimicrobial resistance and the implications for human and animal health one of the matters under consideration
- The regulatory "package";
  - 2001/82 veterinary medicines
  - 1990/167 medicated feeding-stuffs





#### **European Legislative Review**

- Impact assessment and draft legislation for new Veterinary Medicines Regulation/Directive and Medicated Feed Directive expected in late Summer or early Autumn 2014
- Process will then be delayed because of EP elections
- Co decision process follows, amendments etc.
- Will take effect 'on the ground' in late 2017/early 2018





#### **European Legislative review**

- Current European legislation is a Directive
- Transposed into national legislation through the Veterinary Medicines Regulations (VMR)
- If new legislation were to be a directive would be transposed into national legislation through new VMR
- BUT understand new legislation will be a Regulation to be applied directly across EU - means no national 'tweaking'
- Will remain in place for approx. 10 -15 years





#### **Proposals from different sources**

- Proposals to ban prophylactic use from NGOs, UK based MPs, MEPs from Nordics
- RUMA view (supported by NOAH)- Therapy, control and preventive tx needed in vet sector
- Preventive treatment (sometimes referred to as Prophylaxis)
  - Treatment of an animal or a group of animals, before clinical signs of disease, in order to prevent the occurrence of disease or infection.
  - *Preventive treatment with antibiotics should:*
  - only be applied to animals diagnosed at high risk of bacterial disease, and
  - only occur under prescription by a veterinarian on the basis of epidemiological and clinical knowledge, and not be applied routinely, and
  - not be used to compensate for poor hygiene or for inadequate husbandry conditions.





#### **Proposals from different sources**

- Decoupling dispensing by the vet from prescribing latest information NOAH has is this will <u>not</u> be in draft legislation
- However- highly likely that will be proposed as amendments by MEPs, or Member States
- Currently, Nordics, Spain, Italy have decoupled prescribing and dispensing- still large variations in volumes used
- Many Member States oppose splitting prescribing and dispensing as does the OIE





- Use existing legislation to counter inappropriate use
- Minimise preventative use (not prohibit!) justifiable under some circumstances – but never to prop up bad husbandry
- Biosecurity, husbandry, to prevent disease
- RUMA guidelines on responsible use an example
- Increased communication and training increase activity and budget for RUMA and EPRUMA
- Need to retain all available classes for vet use i.e. hope to avoid any bans on critically important antibiotics
- Necessary for animal health and welfare that vets retain access to existing authorised medicines



- Review seen as an opportunity to help improve availability of veterinary medicines across EU
- Increased data protection to promote innovation in the veterinary medicines sector (animal pharma only c. 2% of human pharma market), only 10 years for ROI currently
- Data protection also needed for new claims as well as new molecules e.g. new species
- Many pioneer companies also involved in human pharma
- Regulatory uncertainty and negative climate for vet use likely to encourage even more focus on human medicines





- On the whole UK vets prescribe responsibly transparency at use phase needed
- Gather more data at vet and farm level identify high users and the reasons for high use compared to their peers
- Are the reasons for the high use valid? If not, advice and guidance on measures to reduce use?
- Likely that vets and farmers will need to submit data on antibiotic use to a central point where it will be collated and analysed





- Unexpected treatment failures in veterinary medicine not widespread
- Industry sponsored research CEESA survey backs this view
   <sup>(1)</sup>
- Data needs to be gathered across EU in a harmonised manner, harmonised methodology etc.
- More surveillance needed across EU on both target pathogen resistance and resistance transmission pathways
- Proposals for EU surveillance now being developed by Heads of Medicines Agency Veterinary (HMAv) as per Commission paper
- (1) Ref-A. de Jong, V. Thomas, U. Klein, H. Marion, H. Moyaert, S. Simjee, M. Vallé. Pan-European resistance monitoring programmes encompassing food-borne bacteria and target pathogens of food-producing and companion animals. International Journal of Antimicrobial Agents 41 (2013) 403–409. http://ac.elscdn.com/S0924857912004372/dx.doi.org/10.1016/j.ijantimicag.2012.11.004

- Use new and existing classes strategically
- Treatment choices guided by diagnostics, to minimise resistance development but mandatory use of diagnostics prior to use of Abs - may cause welfare issues – development of pen side tests needed
- Prevention better than cure- farm biosecurity, building design and the use of vaccines
- Ongoing importance of Responsible Use of Medicines in Agriculture Alliance (RUMA)- actively involved in responsible use initiatives and implementation of the UK AMR strategy (EPRUMA in EU)





- Strict interpretation of 'the cascade' required, but critical to retain 'the cascade' for welfare reasons
- Without cascade, minor use and minor species (MUMs) treatment needs unlikely to be met
- Improved regulatory framework- more licensed authorisations will lead to less cascade use
- IFAH Europe proposal for a true single market for veterinary medicines - may reduce need to resort to the cascade
- Need to retain in feed as a route a solution, not a problemimproves welfare, practicalities need to be considered





## Conclusions

- The use of antimicrobials in veterinary medicine will change following legislative review
- Need a full range of antimicrobials to remain available for use in veterinary medicine (responsible use)
- Essential that a range of routes of administration remain available e.g. in-feed
- Need to encourage innovation and investment in vet med sector
- Over zealous use of the 'precautionary principle' has potential to negatively impact innovation and animal health and welfare
- International dimension must be remembered avoid 'exporting food production'



#### Communicating on animal medicines Excerpt from NOAH launch brochure, 1986



Nothing changes!

#### NOAH and its task

SCIENCE AND TECHNOLOGY make massive contributions to everyday life and nowhere more so than in the production of the food we eat.

Modern livestock farming is now more efficient and safe than at any time in history, thanks to the use of vaccines and antibiotics. Huge investment in animal health research and development in the past thirty years has developed controls for all the most serious livestock diseases and stock can now be raised in a healthy and more productive way to the benefit of all.

The companies which make up the National Office of Animal Health (NOAH) are at the forefront of all these improvements for animals and not least in the important pets sector where owners can be confident that their pet can look forward to a healthy, disease-free life.

It is NOAH's chief task to inform and educate the public about animal health and the part played by the companies which produce the products that ensure freedom from disease. NOAH's role is all the more vital given the rise in consumer interest in how our food is produced. Misunderstanding can occur among the public about the need for animal health products. NOAH welcomes informed and rational debate, but it will at all times support that which has been scientifically tested and approved against ill informed comment.

The main concern of animal health companies is to produce safe products for livestock and consumers. The development of new products requires huge financial investment, and many years' work. This investment could be lost at a stroke if the product fails to come to market because of political expediency or the manipulation of consumer fears. If this threat grew too great, companies could be deterred from entering into long term research and animals, farmers and consumers would suffer.

Through liaison with opinion formers, decision makers, government officials, the veterinary profession, distributors and farmers, NOAH will work to convince the public that animal health matters and that the wise use of modern aids actually assists consumer safety.





# What do we know about consumer concerns?

- NOAH commissioned studies through the IGD in 2006 and 2009 which helped us to understand what consumers understood, or perceived about animal medicines in the food chain,
- Following these surveys we updated briefing notes and produced our 'myth busting' document:
  - 'Animal Medicines- What you should know'
- In March 2013, following a further study, again commissioned by IGD, we held a further food chain conference, on working together to dispel the myths of livestock production



## What did we learn?

- Early surveys showed us that consumers had faith in UK farmers
- But some of the perceptions were disappointingly inaccurate – were they perpetuated by ill-informed media?
- Or mischievous lobby groups?
- Or was it because 'we' had not been proactive in our positive communications?



# Positive about farmers and independent checks

73%

British **farmers care** for the health and welfare of their animals

## 60%

Animal medicines are **assessed** and **checked** by independent scientists to ensure they are as safe for people

National Office of Animal Health



Source: IGD Shopper Insight

#### **Uncovering the myths**

1. Medicines/vaccinations getting into food chain

2. Growth hormones used

- Truth -> Lie
- 3. Medicines more necessary in intensive farming

4. Antibiotics becoming less effective for people due to veterinary use





#### Myth: medicines and vaccinations get into food chain



#### Source: IGD Shopper Insight





#### Belief that growth hormones are used





# Increased demand for information on growth hormones



Source: IGD Shopper Insight

#### **Medicines more necessary in intensive farming**



Source: IGD Shopper Insight

National Office of Animal Health

# Antibiotics becoming less effective for people due to use in animals



Source: IGD Shopper Insight

National Office of Animal Healt

#### Daily Mail 4 June 2013

Daily Mail, Tuesday, June 4, 2013

## Are farm animals to blame for the rise of superbugs?

It's normally pinned on doctors handing out antibiotics like sweeties. But there's another, very unsettling theory ...

in preventive veterinary medicine at the University of Cambridge Translational Microbiology unit. The consequences of infection can be devastating. When a brig geta into your biodolitream — perhaps in childhirth, as a result of a wound or setious unpary tract infection — the

CONCERN about superbugs has bed to a haltie about superbugs has bed to a haltie about satisfield in bootcars wait to reserve newer, we control to a superbug experiment of the superbug experiments of the superbug expected of the superbug expected

larms, out the same dimension will being used. Furthermore, though hospital use of two of the best-forown types of broad spectrum drugs (cepha-losporms and the fluoroquinois-nes), which are effective against

make sure our patients finish the dost. Doctors can't do that. We don't have sick cows that need a lot of antibiotic ireatments. They get cuiled. GPs can't do that." How yets cash in by

2

doling out drugs HOWEVER, not all dairy farm are as conscientious as Owen.

y calves are known to ha Dairy caves are known to harbour a high level of antibiotic resistant E.cok bugs. A report has suggested this could be because furners are beeding them on suits hared with thrown away because it comes from cown being treated for mastilis. Piga and poulty secount for nearly file per cent of the farm use of these drugs. The visit importly of pights and chicks get put on anti-biolists from birth because the

these or and the first Presence U equidate and the first Presence U conditions they are relied in pu-thems in inder first of indection. Governments have routing indections and the eccessive u drugs on factory forms, any Tor-Fac (Kolstenk). The three these to be expected on the end of the end beck of the end of the end of the factor of the end of the end of the beam of the end of the end of the beam of the end of the end of the second of the end prevention in poultry fl Dr Mark Hoimes, a fr

To Yanki Biojnes, a forces ret and now a sarrab feature is welterings, the two new MREA strains in generative sectors of the sector of the distance of the sector of the sector of distance of the sector of the sector of the sector of the sector of the problems for humans. He is a low overthe sector of the problems for humans. We is a low overthe sector of the problems for humans. We is a low overthe sector of the problems for humans. We is a low overthe sector of the human sector of the human sector of the producing again, even if it is that's vital for saving burnsn lb 'It is unfair for the regular authorities to expect vets farmers to take the long view w selecting antibiotics.'

#### How do we solve the problem?

the problem? Bo COULD removing the payment insentive out prescribing? Dr Witing about the Danish ackesse were and the control of the Preventing version to the profiling on the oversuse of autistrofics. But the version of a strong -to a strong payment of the But the version of the strong of the strong payment of the the payment of the provided allowed the Danish Agriculture Meating to o farmers using high levels of something similar about the second se the to Save Ou Artibiotics, a campaigning group formed by three charities critical o hetery forming. The problem is that the industry doesn't seem committed to cytting

charities involved. For instance, Britain is the company in the EU that allows companies to advertize anth for animals. This can only ha effect of instreasing sales. Young, (Under pressure fro

using too much and who was using the most dangerous class of drugs, says Dr Aarestrup. But the budget of Britain's industry









#### More consumers are demanding information



Source: IGD Shopper Insight

#### **Two new NOAH videos:**

- Consumer Film Animal Medicines in Food Production – Challenging Consumer Myths
- <u>http://youtu.be/1qluroDR8Ak</u>
- Industry Film Animal Medicines in Food Production – The Food Industry Perspective
- <u>http://youtu.be/UWihGoyJgBI</u>



19 views

Add to



Published on 20 Dec 2013 This firm has been produced by NOAH to help the food industry understand the awareness and concerns consumers have about the use of animal medicines in the food chain.



## Questions?

Contact details Email- <u>p.sketchley@noah.co.uk</u> Telephone- 0208 367 3131



